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Survivin is a novel member of the inhibitor of apoptosis family and determines the susceptibility of tumour cells to pro-
apoptotic stimuli. Recently, we identified two novel alternative splice variants of survivin, differing in their anti-apoptotic
properties: whereas the anti-apoptotic potential of survivin-DEx3 is preserved, survivin-2B has lost its anti-apoptotic potential
and may act as a naturally occurring antagonist of survivin. Because the in vivo expression of these alternative splice variants has
not been explored so far, we analysed gastric carcinomas of different histological subtypes, grades and stages. Since no
antibodies are currently available to determine the novel splice variants, quantitative reverse transcriptase polymerase chain
reaction was performed, using RNA samples obtained from 30 different gastric carcinomas. Polymerase chain reactions
products were quantified by densitometric evaluation. We found that all gastric carcinomas, irrespective of their histological
types, grades or stages, express survivin-DEx3, survivin-2B and survivin, the latter being the dominant transcript. Comparing the
disease stages I+II with III+IV, expression of survivin and survivin-DEx3 remained unchanged. In contrast, a significant (P=0.033)
stage-dependent decrease in the expression of survivin-2B became evident. Our study demonstrates for the first time the
expression of alternative splice variants in gastric carcinomas and provides a first clue to a role of survivin-2B in tumour
progression.
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Increasing resistance to programmed cell death by an imbalance
between pro-apoptotic and anti-apoptotic proteins plays a critical
role during tumorigenesis and tumour progression, facilitating
the accumulation of transforming mutations and promoting
evasion of tumour cells from immunosurveillance (Rudin and
Thompson, 1997). A number of gene products with anti-apoptotic
potential is known to modulate tumour cell viability and resistance
to programmed cell death (Thompson, 1995; Chao and Korsmeyer,
1998; Fadeel et al, 2000). Recently, the inhibitor of apoptosis
protein (IAP) family has been identified that is characterised by
one or multiple domains designated as baculoviral IAP repeats
(BIRs) (Crook et al, 1993; LaCasse et al, 1998). The BIR domain
is considered to be essential for the anti-apoptotic potential of
IAPs, which – inter alia – directly bind and inhibit terminal effec-
tor caspases (Roy et al, 1997; Deveraux and Reed, 1999).
Survivin was identified as a structurally unique member of the
IAP family that contains only a single BIR domain (Ambrosini et
al, 1997). Acting at the interface between apoptosis and mitosis,
survivin was shown to be both a chromosomal passenger protein
(Skoufias et al, 2000) and to prevent programmed cell death by
inhibiting the actions of caspase-3 and caspase-7 (Tamm et al,
1998; Shin et al, 2001). Expression of survivin was found in prolif-
erating foetal tissues, but not in most differentiated adult tissues
(Ambrosini et al, 1997). Remarkably, increased survivin expression
was observed in the most common human neoplasms, including
oesophageal cancer, gastric cancer, colorectal carcinoma, non-small
cell lung cancer, bladder cancer, neuroblastoma and lymphoma
(Adida et al, 1998, 2000; Kawasaki et al, 1998; Lu et al, 1998;
Monzo et al, 1999; Swana et al, 1999; Sarela et al, 2000; Kato et
al, 2001). Expression of survivin may enhance tumour cell viability
during tumour progression and enable the neoplastic cells to over-
come the cytotoxic effects of anticancer drugs. As recently shown
by our group (Mahotka et al, 1999), two novel alternatively spliced
survivin variants, i.e. survivin-DEx3 and survivin-2B, may be rele-
vant for the fine tuning of survivin actions: survivin-DEx3, which
lacks exon 3, exhibits pronounced anti-apoptotic activity, whereas
survivin-2B, which contains a part of intron 2 as an additional
cryptic exon, has largely lost its anti-apoptotic activity. Survivin
variants have also been detected in other species in the meantime
(Conway et al, 2000; Wenzel et al, 2000), suggesting an
evolutionarily conserved mechanism for the regulation of survivin
actions by alternative splicing.
Whereas expression of survivin has previously been observed in
gastric cancer (Lu et al, 1998), no data are available so far on the
role of survivin-DEx3 and survivin-2B in this cancer type. There-
fore, we quantified the expression levels of the different survivin
variants in a panel of 30 gastric carcinomas. Because no antibodies
are currently available that discriminate between the different
survivin variants on the protein level, we used a survivin-specific
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reverse transcriptase polymerase chain reaction (RT – PCR) for our
analysis. This study provided first ex vivo evidence for a role of
survivin-2B in the progression of gastric cancer.
MATERIALS AND METHODS
Patients and specimens
Tissue samples of 30 consecutive gastric carcinomas were obtained
from patients who had undergone gastrectomy. The tumour speci-
mens were immediately flash frozen in liquid nitrogen and stored
at 7808C until total RNA extraction or protein isolation was
performed. Tumour typing, grading and staging were performed
according to the principles outlined by the WHO (Watanabe et
al, 1998) and the UICC (Sobin and Wittekind, 1997). Additional
clinicopathological parameters such as age, sex, lymphatic vessel
invasion, blood vessel invasion, Helicobacter pylori colonisation
and density of the chronic inflammatory cell infiltration in the
tumour-adjacent normal gastric mucosa (according to the Sydney
System (Dixon et al, 1996)) were defined for all patients.
RNA – extraction
Total RNA of the tumours and paired non-neoplastic tissue
samples was isolated by acid guanidium thiocyanate phenol chloro-
form extraction with minor modifications as previously described
(Chomczynski and Sacchi, 1987).
Reverse transcription and polymerase chain reaction
Total RNA (2 mg) was reversely transcribed in a final 30 ml reaction
volume using 5 U AMV reverse transcriptase (Promega, Heidel-
berg, Germany), 16RT buffer (Promega), 20 U of RNase
inhibitor RNAsin (Promega), 25 mM of each deoxynucleotide
triphosphate (Qiagen, Hilden, Germany) and 10 pmol of each
sequence-specific RT primer. Because survivin mRNA has to be
distinguished from effector cell protease receptor-1 (EPR-1)
mRNA, a naturally occurring antisense-mRNA of survivin which
might bias survivin amplification (Zaman and Conway, 2000), we
used the primer 5’-AGG AAC CTG CAG CTC AGA-3’, corre-
sponding to nucleotides 914 – 931 of the survivin antisense strand
(accession no NM_001168). For GAPDH-specific cDNA synthesis,
the antisense primer 5’-CTC CTG GAA GAT GGT GAT GG-3’,
corresponding to nucleotides 251 – 270 of the GAPDH antisense
strand (accession no J04038) was used. Reverse transcription of
survivin and GAPDH was performed in the same reaction to avoid
variations in efficiency of cDNA synthesis. The specific RT reaction
mixtures were incubated at 508C for 1 h. PCR amplification was
performed in a final volume of 50 ml containing 3 ml first strand
cDNA solution, 2.5 U of Taq polymerase, 16PCR-buffer, 10 ml
Q-solution (except GAPDH amplification), 25 mM of each dNTP
(all Qiagen) and 25 pmol of each 3’ and 5’ sequence specific oligo-
nucleotide primer.
To determine the saturation phase of RT – PCR amplification,
we started with a cycle titration for survivin and GAPDH. Reac-
tions were stopped after 15, 20, 25, 30, 35 and 40 cycles, and the
PCR products of the different cycle numbers were electrophoresed
on 3% agarose gels containing ethidium bromide. The signal inten-
sity of amplification products was quantified by densitometry as
described below. PCR was then performed for all cDNA samples
with 35 (survivin) or 25 cycles (GAPDH), which did not reach
the saturation phase and permitted the densitometric quantifica-
tion and comparison of amplification product levels.
Survivin-PCR amplification was performed on a PTC-100 Ther-
mal controller (Biozym Diagnostic, Hess, Oldendorf, Germany)
with initial denaturation at 958C for 2 min, followed by 35 cycles
of denaturation at 948C for 30 s, annealing for 1 min at 588C,
extension at 728C for 1 min and a final extension at 728C for
5 min. GAPDH – PCR amplification conditions were identical to
those described above except annealing at 648C and 25 cycles.
Primers were designed to amplify the entire coding region of survi-
vin: 5’-GCA TGG GTG CCC CGA CGT TG-3’ (forward;
corresponding to position 48 – 67 of the survivin mRNA; accession
no NM_001168) and 5’-GCT CCG GCC AGA GGC CTC AA-3’
(reverse). RT – PCR for GAPDH as a constitutively expressed gene
was performed using the primers 5’-ACG GAT TTG GTC GTA
TTG GGC G-3’ (forward; corresponding to position 59 – 80; acces-
sion no J04038) and 5’-CTC CTG GAA GAT GGT GAT GG-3’
(reverse). PCR products were electrophoresed on 3% agarose gels
containing ethidium bromide and visualised under UV-transillumi-
nation.
All RT – PCR amplifications were carried out in duplicate to
confirm reproducibility. To ensure that amplification of survivin
and GAPDH was specific, PCR bands were excised from agarose
gels and isolated using the QIAquick gel extraction kit (Qiagen).
The purified PCR-products were sequenced using the ABI-Prism
BigDye Terminator Cycle Sequencing Kit (Applied Biosystems,
Weiterstadt, Germany) and the oligonucleotides designed for
PCR amplification. Sequence analysis was performed with a ABI-
Prism 310 sequencer (Applied Biosystems).
Quantification of PCR – products and statistical analysis
Electrophoresed and ethidium bromide stained PCR products from
two independent RT – PCR reactions were recorded under UV-
transillumination by the Gel-Doc 1000 apparatus (Bio-Rad,
Mu¨nchen, Germany) and quantified by densitometric evaluation
of signal intensity using the Kodak Digital Science 1D software.
GAPDH mRNA levels were used to normalise the mRNA levels
of the different survivin variants, calculating relative mRNA levels
as the ratios between survivin variants and GAPDH.
Immunoblotting
Protein extracts from four arbitrarily selected gastric carcinomas
were isolated by disrupting flash frozen tissue samples in lysis
buffer (100 mM NaCl, 10 mM Tris-HCl pH 7.6, 1 mM EDTA
pH 8, 1% NP40 and protease-inhibitor). Protein aliquots
(100 mg) were electrophoresed through 15% SDS-polyacrylamide
gels at 70 mA for 4 h. Blotting to Optitran BA-S85 nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany) was
performed for 1.5 h at 650 mA in a tank of transfer buffer
pH 8.3 (25 mM Tris-HCl, 192 mM Glycin, 20% Methanol) using
the Hoefer TE series Transphor electrophoresis Unit (Hoefer Scien-
tific instruments, San Francisco, CA, USA). To verify transfer
efficiency and protein integrity, nitrocellulose membranes were
stained with Ponceau S 0.2%. The membranes were blocked over
night in blocking buffer (100 mM Tis-HCl, pH 7.5, 150 mM NaCl,
0,2% Tween 20) plus 3% non-fat dry milk and 1% BSA, incubated
for 2 h at room temperature with the polyclonal rabbit anti-human
survivin antibody SURV 11-A (Alpha Diagnostic International Inc,
San Antonio, TX, USA; dilution: 1 : 1000), washed, and incubated
with a 1 : 2000 dilution of horseradish peroxidase-linked donkey
anti-rabbit antibody for 1 h at room temperature. After washing,
protein detection was performed by incubation with Lumi-Light
substrate (Roche, Mannheim, Germany). Equal amounts of the
loaded samples were confirmed by b-actin detection with the
monoclonal mouse anti-human b-actin antibody (Sigma-ldrich,
Deisenhofen, Germany; clone AC-15). Data on X-ray films were
quantified by densitometry.
Statistical analysis
For statistical analysis, disease stages were defined according to the
principles outlined by the UICC (Sobin and Wittekind, 1997) and
disease stages I and II were compared with disease stages III and
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IV. Statistical analysis was performed using the SPSS 9.0 software
package (SPSS Inc., Chicago, IL, USA). The expression of the
different survivin-variants in cancer tissues was compared by the
Wilcoxon-test. Correlation between the expression levels of survi-
vin variants and clinicopathological variables was examined using
the nonparametric Mann – Whitney-test. A two-tailed P-value less
than 0.05 was considered to indicate statistical significance.
RESULTS
Expression of survivin variants
Expression of survivin and its alternative splice variants (survi-
vin-DEx3 and survivin-2B) was detectable in all gastric cancer
specimens (n=30), irrespective of their histological types, grades
and stages (Figure 1A). Because we had applied cycle numbers
for PCR amplification of survivin and GAPDH that did not
reach the saturation phase, a densitometric evaluation and
comparison of the mRNA levels between different tissue samples
was feasible. As shown in Figure 1B, survivin was the predomi-
nant transcript variant, whereas only low levels of survivin-DEx 3
and survivin-2B were observed. The differences of expression
between the survivin variants were statistically significant
(P50.001).
Fourteen matched pairs of non-neoplastic and neoplastic gastric
tissue samples were compared for their expression of survivin
variants. In eight out of 14 non-neoplastic tissue samples, no or
barely detectable levels of survivin mRNA levels were observed.
Survivin expression in each cancer tissue sample exceeded that of
the matched non-neoplastic tissue sample (Figure 2A), the overall
expression levels in cancer being significantly higher (P=0.005)
when compared to non-neoplastic tissues (Figure 2B). Whereas
survivin-DEx3 expression did not significantly differ between
non-neoplastic and neoplastic tissue samples (P=0.059), survivin-
2B expression was significantly (P=0.02) elevated in gastric carcino-
mas (Figure 2B).
Stage-dependent decrease in survivin-2B expression
Survivin expression has previously been reported to be related to
prognosis of cancer patients (Adida et al, 1998, 2000; Kawasaki
et al, 1998; Monzo et al, 1999; Swana et al, 1999; Sarela et al,
2000; Kato et al, 2001). Therefore, we analysed the stage-depen-
dent expression of the different survivin variants, comparing low
stages (I+II according to UICC (Sobin and Wittekind, 1997))
and advanced stages (III and IV according to UICC (Sobin
and Wittekind, 1997)) of gastric cancer. As shown in Figure 3,
the expression levels of the anti-apoptotic survivin variants (i.e.
survivin and survivin-DEx3) did not significantly change between
low (I+II) and advanced (III+IV) tumour stages. In contrast, a
significant (P=0.033) decrease in the expression of the non-
anti-apoptotic survivin-2B variant became evident in advanced
stages of gastric cancer. To ensure that the stage-dependent
decrease of survivin-2B expression was not the result of a
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Figure 1 RT – PCR amplification (A) and relative (GAPDH-normalised) mRNA levels (B) of survivin and its alternative splice variants in gastric cancer.
(A) Two mg of total RNA was reversely transcribed and amplified by polymerase chain reaction. PCR-products were electrophoresed and visualised by
ethidium bromide staining. Four arbitrarily selected examples of each UICC disease stage are shown. M, molecular weight marker; NC, negative control
(H2O); survivin (431 bp); survivin-2B (500 bp); survivin-DEx3 (329 bp). (B) Survivin is the dominant transcript. P-values were calculated by the Wilcox-
on-test.
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stage-dependent increase of GAPDH transcripts used as an exter-
nal standard, we additionally calculated the ratios of mRNA
levels between survivin-DEx3 or survivin-2B on one hand and
survivin as an internal standard on the other hand. Because all
survivin variants are derived from a common hnRNA precusor
pool, these ratios are independent from a possible bias imposed
by possible variations of GAPDH expression levels. The differ-
ence between these ratios (P=0.037) further confirmed the
significant stage-dependent decrease of non-anti-apoptotic survi-
vin-2B (Figure 4).
Correlation between the expression levels of survivin
variants and clinicopathological parameters
To detect a possible correlation between the expression levels of
survivin variants and other clinicopathological parameters, the
Mann – Whitney-test for nonparametric data was performed. With
the exception of the stage-dependent decrease in the expression of
survivin-2B (see above), none of the investigated clinicopathologi-
cal variables showed a statistically significant correlation with the
expression levels of survivin and its alternative splice variants
(Table 1).
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Figure 2 RT – PCR-amplification (A) and relative (GAPDH-normalised)
mRNA levels (B) of survivin variants in paired samples of non-neoplastic
(N) and neoplastic (T) gastric tissue. (A) In eight out of 14 non-neoplastic
tissue samples, no or barely detectable levels of survivin mRNA levels were
observed. In each cancer tissue sample, survivin expression level exceeded
that of the corresponding non-neoplastic tissue sample. GAPDH served as
internal control. (B) Expression of survivin and survivin-2B – but not sur-
vivin-DEx3 - are elevated in gastric carcinomas. Two-tailed P-values were
calculated by the Mann – Whitney-test.
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Figure 3 Relative (GAPDH-normalised) mRNA levels of the different
survivin variants in gastric carcinomas of different stages. A significant de-
crease in the expression of survivin-2B is found in advanced disease stages.
Two-tailed P-values were calculated by the Mann – Whitney-test.
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Expression of survivin protein in gastric carcinomas
Because no antibodies are available so far which recognise survivin-
2B and survivin-DEx3, we could only analyse the expression of
survivin protein in four arbitrarily selected gastric carcinoma
samples that represent the UICC stages I to IV. All tissue samples
showed survivin protein, but no uniform increase of survivin
expression became evident in more advanced tumour stages
(Figure 5).
DISCUSSION
In this study, we show that all tissue specimens of gastric cancer
express the apoptosis inhibitor survivin and extend a previous
report by Lu et al (1998) on survivin protein expression in
34.5% of gastric cancer cases to all cases of our study on the
mRNA level, using the more sensitive RT – PCR technique. More
importantly however, we demonstrate for the first time that the
novel splice variants survivin-Ex3 and survivin-2B are expressed
in ex vivo tumour samples of gastric cancer.
Recently, survivin has been identified as a structurally and func-
tionally unique member of the inhibitor of apoptosis protein (IAP)
family that is highly conserved during evolution (Wenzel et al,
2000) and involved in the regulation of both apoptosis and cell
cycle progression (Li et al, 1998, 1999). At variance with the
ubiquitous distribution of other IAPs in foetal and adult tissues,
intensive survivin expression in proliferating foetal tissues contrasts
with down-regulation in most differentiated adult tissues (Ambro-
sini et al, 1997). Most strikingly, however, expression of survivin
was found in the most common human cancer types, which might
promote both tumour progression and resistance to chemotherapy
and irradiation. The molecular mechanisms by which survivin inhi-
bits apoptosis are still under investigation. In vitro experiments
have shown that survivin binds and inhibits the cell death effector
proteases caspase-3 and caspase-7 (Tamm et al, 1998; Shin et al,
2001). Moreover, survivin was found to associate specifically with
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Figure 4 Ratio of relative mRNA levels between the different survivin
variants in gastric carcinomas. Significant decrease of the survivin-2B/survi-
vin ratio in advanced (III+IV) tumour stages. Two-tailed P-values were cal-
culated by the Mann – Whitney-test.
Table 1 Correlation between expression levels of survivin variants and
clinicopathological parameters
No. of
P-value
Variables patients Survivin Survivin-DEx3 Survivin-2B
Stage (UICC)a
I+II 15 0.152 0.237 0.033
III+IV 15
Histological grade
G1b+G2 9 0.428 0.982 0.067
G3+G4b 21
Histological type
Intestinal 16 0.645 0.272 0.231
Diffuse 11
Mixed c
Lymphatic vessel invasion
Positive 20 0.860 0.509 0.895
Negative 10
Blood vessel invasion
Positive 8 0.399 0.223 0.281
Negative 22
Helicobacter pylori infection
Positive 14 0.561 0.739 0.430
Negative 16
Chronic inflammationd
Present 19 0.098 0.237 0.333
Absent 11
Age
465 years 16 0.183 0.135 0.135
465 years 14
Sex
Female 10 0.428 0.895 0.598
Male 20
aDepth of infiltration: pT1: n=2; pT2: n=19; pT3: n=8; pT4: n=1. Lymph node
involvement: pN0: n=5; pN1: n=14; pN2: n=5; pN3: n=6. Distant metastasis: M0:
n=2; M1: n=5. bOnly one case. cNot included in statistical analysis due to the
low case number. dAccording to the Sydney System.
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Figure 5 Expression of survivin protein in gastric carcinomas. One hun-
dred mg protein of each tumour sample were assessed for survivin and b-
actin expression. Grey bars reflect the relative expression levels of survivin
as measured by densitometry.
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centromeres, microtubules of the mitotic spindle and Cdk4, there-
by supposedly regulating the progression of foetal and neoplastic
cells through mitosis (Li et al, 1998; Suzuki et al, 2000; Uren et
al, 2000; Wheatley et al, 2001).
The complexity of survivin actions is further augmented by the
expression of two functionally divergent alternative splice variants,
i.e. survivin-DEx3 and survivin-2B. As recently demonstrated by
our group (Mahotka et al, 1999), both splice variants exhibit struc-
tural alterations of their single BIR domain. Despite these
structural modifications, the anti-apoptotic potential of survivin-
DEx3 seems to be largely preserved, whereas survivin-2B exhibited
a loss of anti-apoptotic properties and, therefore, might act as a
naturally occurring antagonist of survivin (Mahotka et al, 1999).
Although further experimental work is necessary to elucidate the
functional properties of the different splice variants in more detail,
first clues to the involvement of survivin-DEx3 and survivin-2B in
the progression of gastric carcinoma can be derived from our
present study.
In this study, we found mRNA expression of the anti-apoptotic
variants survivin and survivin-DEx3 in all major histological types
of gastric carcinomas, irrespective of their grading and staging.
Analysis of matched pairs of non-neoplastic and neoplastic tissue
samples revealed expression of both survivin variants in non-
neoplastic gastric tissues and a significant increase in survivin –
but not survivin-DEx3 – mRNA expression levels in cancer tissue.
Especially the use of more sensitive RT – PCR has demonstrated
survivin expression in other non-neoplastic tissues as well, includ-
ing normal lung samples, endothelial cells and lymphocytes
(Monzo et al, 1999; Tran et al, 1999; Kornacker et al, 2001). The
low levels of survivin mRNA in non-neoplastic tissues argue against
the assumption that increased survivin levels in gastric cancer
might only be due to an increased proportion of lymphocytes.
Our observations, therefore, further confirmed the ubiquitous
increase of survivin expression in human cancer as previously
reported for other tumour types as well (Adida et al, 1998, 2000;
Kawasaki et al, 1998; Lu et al, 1998; Monzo et al, 1999; Swana et
al, 1999; Sarela et al, 2000; Kato et al, 2001).
Increased survivin mRNA or protein expression has previously
been reported to be a prognostic indicator of tumour progression
in different types of human cancer (Adida et al, 1998, 2000; Kawa-
saki et al, 1998; Monzo et al, 1999; Swana et al, 1999; Sarela et al,
2000; Kato et al, 2001). The densitometric quantification of mRNA
levels performed in our study, however, did not reveal a correlation
between expression levels of survivin and the histological types,
grades or stages of gastric carcinomas. This observation was further
supported by Western blot analysis of arbitrarily selected gastric
carcinomas, and is in accordance with a previous immunohisto-
chemical analysis of gastric cancer (Lu et al, 1998), which failed
to reveal a significant correlation between survivin expression
and tumour depth, lymph node metastasis or disease stage.
Increased expression of anti-apoptotic survivin, therefore, might
be an early event in gastric carcinogenesis, as has formerly been
suggested for survivin in other tumour types as well (Grossman
et al, 1999).
In accordance with our observations in renal carcinoma cell
lines (Mahotka et al, 1999), the mRNA levels of survivin-2B in
gastric carcinomas were significantly lower than those of survivin.
Moreover, the expression of survivin-2B significantly decreased in
advanced stages of gastric cancer. These low levels of survivin-2B
expression, however, might not reflect the actual significance of
survivin-2B for the progression of gastric cancer. Thus, the stage-
dependent downregulation of survivin-2B might affect the suscept-
ibility to apoptosis induction in two ways. The decrease of
survivin-2B transcripts could permit the generation of more anti-
apoptotic survivin variants (i.e. survivin and survivin-DEx3),
because all survivin variants originate from a common pool of a
hnRNA percusor. Parallel to the decrease of survivin-2B, the
anti-apoptotic effects of survivin could become even more pre-
dominant, if survivin-2B actually acts as a natural antagonist as
suggested by Islam et al (2000).
In conclusion, our study presents first data on the in vivo
expression of novel survivin splice variants in gastric carcinomas.
Expression of survivin-2B – but not of survivin and survivin-
DEx3 – was shown to be related to tumour progression in gastric
cancer. These findings indicate for the first time that alternative
splice variants of survivin may be involved in the fine tuning of
survivin actions in gastric carcinomas.
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